Mangoceuticals Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement and Comments on Nuclea Energy Business Combination
Rhea-AI Summary
Mangoceuticals (NASDAQ: MGRX) received a 180-day Nasdaq extension to regain compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2). The company now has until February 1, 2027 for its stock to close at or above $1.00 for at least 10 consecutive business days.
Nasdaq granted the extension after Mangoceuticals met other listing and market value requirements and provided written notice that it may use a reverse stock split, if needed. The company also continues to advance its definitive business combination agreement with Nuclea Energy, which is developing the Morpheus lead‑cooled micro modular reactor.
Positive
- 180-day Nasdaq extension to regain $1.00 minimum bid price compliance
- Nasdaq confirms Mangoceuticals meets all other initial listing requirements for the Capital Market
- Company continues advancing definitive business combination agreement with Nuclea Energy
Negative
- Shares remain below $1.00 bid price, risking eventual Nasdaq delisting if compliance is not regained
- Regaining compliance may require a reverse stock split, which can be dilutive in perception for shareholders
- Compliance must be restored by February 1, 2027, creating a fixed timeline and execution pressure
News Explained
As of March 31, 2026, reported cash was $174,562, equating to 12 days of quarterly operating cash use.
The release leaves Mangoceuticals at an extension stage: the reverse split is only a possible cure, and the proposed Nuclea combination is not reported as closed.
A reverse stock split consolidates shares, raising the per-share price and reducing the share count proportionally; the split itself does not change company value.
As of
The stated resolution points are the SEC registration statement and proxy materials for the proposed transaction, plus the
Sources and calculations
- Mangoceuticals Nasdaq extension and Nuclea business combination release (2026-08-04)
- Reverse stock split definition (2026-07-17)
- Mangoceuticals first-quarter fundamentals (2026-03-31)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $174,562 / ($1,311,343 / 90) = [object Object]
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Lawsuit announcement | Negative | -7.0% | Company sought damages exceeding $73 million from former technology consulting firm. |
| Mar 06 | Patent filing | Positive | -7.0% | Company filed international patent application for MGX-0024 antiviral animal technology. |
| Feb 23 | Clinical data | Positive | -3.9% | MGX-0024 showed zero respiratory mortality in approximately 29,000 treated broiler chickens. |
| Feb 19 | TRT program launch | Positive | +48.8% | New injectable testosterone program reported sales growth and reduced customer acquisition cost. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The stock aligned with negative legal news but diverged from positive technology and clinical announcements.
Key Terms
reverse stock split financial
business combination agreement financial
micro modular reactor technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dallas, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced it has received an additional 180-calendar-day extension from the Nasdaq Stock Market (“Nasdaq”) to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2).The Company now has until February 1, 2027 to meet the requirement for its shares of common stock to maintain a closing bid price of at least US
This news comes as the Company continues to advance its previously announced definitive business combination agreement with Nuclea Energy Inc., an advanced nuclear technology company developing the Morpheus microreactor, a lead cooled, factory built micro modular reactor designed to meet growing demand for reliable, carbon free power from AI infrastructure, data centers, and other applications.
Jacob D. Cohen, Chief Executive Officer of Mangoceuticals, commented: “We appreciate Nasdaq’s decision to grant this extension, which provides Mangoceuticals with continued flexibility as we advance our operational and strategic objectives with Nuclea Energy representing a transformative opportunity. We further look forward to bringing meaningful value to shareholders through exposure to the advanced nuclear sector and the commercialization potential of the Morpheus microreactor. We will continue to provide the market with further updates as they develop, and we thank our shareholders for their continued patience and support.”
The Company remains committed to full compliance with all Nasdaq listing requirements and will continue to monitor its share price closely. Mangoceuticals plans to take all necessary actions within the prescribed period to regain compliance.
About Mangoceuticals, Inc.
MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company currently offers pharmaceutical-based products specifically related to the treatments of erectile dysfunction, hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a licensed medical provider and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com.
Additional Information
In connection with the proposed transaction, Mangoceuticals intends to file relevant materials with the SEC, including a registration statement containing a proxy statement in connection with the stockholder approval described above. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of these documents through the website maintained by the SEC at www.sec.gov, or by directing a request to Mangoceuticals.
Participants in the Solicitation
Mangoceuticals, Nuclea and their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from Mangoceuticals’ stockholders in connection with the transaction. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of Mangoceuticals’ executive officers and directors in its most recent Annual Report on Form 10-K and other filings with the SEC. Additional information regarding the persons who may be deemed participants in the solicitation and their interests will be set forth in the proxy statement and other relevant materials when they become available.
No Offer or Solicitation
This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the proposed transaction and its expected structure, timing and completion; the anticipated ownership percentages of Mangoceuticals following closing; the anticipated benefits of the transaction to Mangoceuticals’ stockholders; projected electricity demand; and the development, licensing, commercialization and performance of the Morpheus microreactor, which remains in the conceptual design stage. Forward-looking statements are based on current expectations and assumptions and are subject to significant risks and uncertainties, including the risk that the transaction may not be completed on the anticipated terms or timing, or at all; the ability to obtain required regulatory, Nasdaq and stockholder approvals; the ability to obtain nuclear licensing approvals; the availability of capital; and technology development risks. Actual results may differ materially from those expressed or implied. Neither Mangoceuticals nor Nuclea undertakes any obligation to update forward-looking statements except as required by law.
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
